Relistor Finally Cleared For Bigger Opioid-Induced Constipation Label
This article was originally published in The Pink Sheet Daily
Executive Summary
Extended bid for an sNDA of Progenics/Salix’ subcutaneous Relistor for chronic non-cancer pain ends in success, but Nektar/AstraZeneca’s recently-approved oral Movantik is expected to dominate the market. Regulatory path for Phase III oral Relistor is still unclear.
You may also be interested in...
Valeant’s Oral Relistor Poised To Face-Off Against AstraZeneca’s Movantik
FDA approval of the first oral form of Valeant’s mu-opioid receptor antagonist Relistor will pit the franchise against Movantik for the treatment of patients with opioid-induced constipation with non-cancer pain.
AstraZeneca’s Movantik Clears FDA; Launch On Hold Pending DEA Action
Naloxegol is currently a Schedule II controlled substance due to its structural similarity to another compound; AstraZeneca seeks descheduling of the constipation drug, which labeling states poses no risk of abuse or dependency.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.